{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T22:06:06Z","timestamp":1792879566802,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["FOR 2674 A05 BE 6461\/1-2"],"award-info":[{"award-number":["FOR 2674 A05 BE 6461\/1-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["FOR 2674 A02"],"award-info":[{"award-number":["FOR 2674 A02"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["LU 429\/16-2"],"award-info":[{"award-number":["LU 429\/16-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["NanodiagBW P3"],"award-info":[{"award-number":["NanodiagBW P3"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["EkoEstMed\u2013FKZ 01ZZ2015"],"award-info":[{"award-number":["EkoEstMed\u2013FKZ 01ZZ2015"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["PM4Onco\u2013FKZ 01ZZ2322A"],"award-info":[{"award-number":["PM4Onco\u2013FKZ 01ZZ2322A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005677","name":"Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung","doi-asserted-by":"publisher","award":["17\u2009R\/2019"],"award-info":[{"award-number":["17\u2009R\/2019"]}],"id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005677","name":"Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung","doi-asserted-by":"publisher","award":["AH06-01"],"award-info":[{"award-number":["AH06-01"]}],"id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41375-025-02780-7","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T06:19:21Z","timestamp":1759817961000},"page":"2816-2819","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trial"],"prefix":"10.1038","volume":"39","author":[{"given":"Inga","family":"Hund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5792-3657","authenticated-orcid":false,"given":"Maria Elena","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5389-9481","authenticated-orcid":false,"given":"Geoffroy","family":"Andrieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3858-4385","authenticated-orcid":false,"given":"Julia","family":"Stomper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Greve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Niem\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1258-8976","authenticated-orcid":false,"given":"Tobias","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Uhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Grishina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5848-6152","authenticated-orcid":false,"given":"Felicitas","family":"Thol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5318-9044","authenticated-orcid":false,"given":"Michael","family":"Heuser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2359-131X","authenticated-orcid":false,"given":"Gesine","family":"Bug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Crysandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7606-8760","authenticated-orcid":false,"given":"Andreas","family":"Neubauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7325-7753","authenticated-orcid":false,"given":"Justus","family":"Duyster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2116-5536","authenticated-orcid":false,"given":"Hartmut","family":"D\u00f6hner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3670-0602","authenticated-orcid":false,"given":"Melanie","family":"Boerries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1186-1650","authenticated-orcid":false,"given":"Michael","family":"L\u00fcbbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6919-4048","authenticated-orcid":false,"given":"Heiko","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"2780_CR1","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3324\/haematol.2011.048231","volume":"97","author":"M L\u00fcbbert","year":"2012","unstructured":"L\u00fcbbert M, R\u00fcter BH, Claus R, Schmoor C, Schmid M, Germing U, et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica. 2012;97:393\u2013401.","journal-title":"Haematologica"},{"key":"2780_CR2","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30:2670\u20137.","journal-title":"J Clin Oncol"},{"key":"2780_CR3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"2780_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1200\/JCO.19.01053","volume":"38","author":"M L\u00fcbbert","year":"2020","unstructured":"L\u00fcbbert M, Grishina O, Schmoor C, Schlenk RF, Jost E, Crysandt M, et al. Valproate and retinoic acid in combination with decitabine in elderly nonfit patients with acute myeloid leukemia: results of a multicenter, randomized, 2 \u00d7 2, phase II trial. J Clin Oncol. 2020;38:257\u201370.","journal-title":"J Clin Oncol"},{"key":"2780_CR5","first-page":"1032","volume":"9","author":"AP Stegmann","year":"1995","unstructured":"Stegmann AP, Honders MW, Willemze R, Landegent JE. De novo induced mutations in the deoxycytidine kinase (dck) gene in rat leukemic clonal cell lines confer resistance to cytarabine (AraC) and 5-aza-2\u2019-deoxycytidine (DAC). Leukemia. 1995;9:1032\u20138.","journal-title":"Leukemia"},{"key":"2780_CR6","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41375-020-1003-x","volume":"35","author":"X Gu","year":"2021","unstructured":"Gu X, Tohme R, Tomlinson B, Sakre N, Hasipek M, Durkin L, et al. Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network. Leukemia. 2021;35:1023\u201336.","journal-title":"Leukemia"},{"key":"2780_CR7","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1159\/000513696","volume":"144","author":"B Wu","year":"2021","unstructured":"Wu B, Mao ZJ, Wang Z, Wu P, Huang H, Zhao W, et al. Deoxycytidine kinase (dck) mutations in human acute myeloid leukemia resistant to cytarabine. Acta Haematol. 2021;144:534\u201341.","journal-title":"Acta Haematol"},{"key":"2780_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11413-4","volume":"10","author":"T Oellerich","year":"2019","unstructured":"Oellerich T, Schneider C, Thomas D, Knecht KM, Buzovetsky O, Kaderali L, et al. Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML. Nat Commun. 2019;10:3475.","journal-title":"Nat Commun"},{"key":"2780_CR9","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1111\/bjh.15461","volume":"182","author":"JM Stosch","year":"2018","unstructured":"Stosch JM, Heum\u00fcller A, Niem\u00f6ller C, Bleul S, Rothenberg-Thurley M, Riba J, et al. Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment. Br J Haematol. 2018;182:830\u201342.","journal-title":"Br J Haematol"},{"key":"2780_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/ejh.14304","volume":"114","author":"H Bresser","year":"2025","unstructured":"Bresser H, Schmoor C, Grishina O, Pfeifer D, Thomas J, Rehman U, et al. Impact of TP53 mutation status in elderly AML patients when adding all-trans retinoic acid or valproic acid to decitabine. Eur J Haematol. 2025;114:231\u20137.","journal-title":"Eur J Haematol"},{"key":"2780_CR11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415\u201321.","journal-title":"Nature"},{"key":"2780_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09633-9","volume":"10","author":"S Gr\u00f6schel","year":"2019","unstructured":"Gr\u00f6schel S, H\u00fcbschmann D, Raimondi F, Horak P, Warsow G, Fr\u00f6hlich M, et al. Defective homologous recombination DNA repair as therapeutic target in advanced chordoma. Nat Commun. 2019;10:1635.","journal-title":"Nat Commun"},{"key":"2780_CR13","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.ccell.2016.09.002","volume":"30","author":"NE Muvarak","year":"2016","unstructured":"Muvarak NE, Chowdhury K, Xia L, Robert C, Choi EY, Cai Y, et al. Enhancing the cytotoxic effects of PARP inhibitors with DNA demethylating agents\u2013a potential therapy for cancer. Cancer Cell. 2016;30:637\u201350.","journal-title":"Cancer Cell"},{"key":"2780_CR14","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1158\/1078-0432.CCR-21-3729","volume":"28","author":"MR Baer","year":"2022","unstructured":"Baer MR, Kogan AA, Bentzen SM, Mi T, Lapidus RG, Duong VH, et al. Phase I clinical trial of DNA methyltransferase inhibitor decitabine and PARP inhibitor talazoparib combination therapy in relapsed\/refractory acute myeloid leukemia. Clin Cancer Res. 2022;28:1313\u201322.","journal-title":"Clin Cancer Res"},{"key":"2780_CR15","doi-asserted-by":"publisher","unstructured":"Rolles B, Chatain N, G\u00f6rg R, Vieri M, Tillmann-Tr\u00f6ster N, Bourgeois MG, et al. ZIP10 as a potential therapeutic target in acute myeloid leukaemia. Br J Haematol 2025; https:\/\/doi.org\/10.1111\/bjh.20229.","DOI":"10.1111\/bjh.20229"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02780-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02780-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02780-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:34:34Z","timestamp":1762331674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02780-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2780"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02780-7","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"8 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HB: honoraria from AbbVie, Bristol Myers Squibb, GlaxoSmithKline, Lilly, Merck Sharp & Dohme, Novartis, Pierre Fabre Pharma, and Servier. HD: consultancy (AdBoard) with honoraria for AbbVie, Otsuka, Pfizer, Servier, Syndax; and clinical research funding to the institution from AbbVie, Astellas, Bristol Myers Squibb, Jazz Pharmaceuticals, Servier; and travel\/ accommodation expenses from AbbVie, Servier. The remaining authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All study methods were performed in accordance with relevant guidelines and regulations. Ethics approval was obtained from the Ethics Committee at the University of Freiburg (76\/10-120689). Written informed consent was obtained from all subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}